The Experts below are selected from a list of 1442193 Experts worldwide ranked by ideXlab platform

Maldonado Rozo Adriana - One of the best experts on this subject based on the ideXlab platform.

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    2020
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.Instituto de Física de Líquidos y Sistemas Biológico

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    'Corporacion Universitaria Autonoma del Cauca', 2018
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.Fil: Espinosa Silva, Yanis Ricardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Física de Líquidos y Sistemas Biológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Física de Líquidos y Sistemas Biológicos; ArgentinaFil: Galvis, Fredy. Universidade de Sao Paulo; BrasilFil: Maldonado Rozo, Adriana. Universidad Nacional de Colombia; Colombi

Eric Dumonteil - One of the best experts on this subject based on the ideXlab platform.

  • patterns of house infestation dynamics by non domiciliated triatoma dimidiata reveal a spatial gradient of infestation in rural villages and potential insect manipulation by trypanosoma cruzi
    Tropical Medicine & International Health, 2010
    Co-Authors: Maria Jesus Ramirezsierra, Melba Herreraaguilar, Sebastien Gourbiere, Eric Dumonteil
    Abstract:

    Summary Objective  Chagas disease is a major vector-borne parasitic disease in Latin America, primarily transmitted to humans by triatomine vectors. Non-domiciliated triatomine species such as Triatoma dimidiata in the Yucatan peninsula, Mexico, can transiently invade houses and are emerging as a major challenge to control Trypanosoma cruzi transmission to humans. We analyzed the spatio-temporal spreading of house infestation by T. dimidiata in four rural villages. Methods  Triatomines were collected in four rural villages over a 2 years period, and the spatio-temporal patterns of infestation were analyzed. Results  Triatomines were consistently more abundant at the periphery of villages than in centers, indicating a much higher risk of T. cruzi transmission at the periphery. Male T. dimidiata were found further in the center of the village, while females remained closer to the periphery, suggesting differential dispersal capabilities between sexes, although the timing of dispersal appeared identical. Surprisingly, infected females were consistently collected in houses much further from the surrounding bushes than non-infected females, while the distribution of males was unaffected by their T. cruzi infection status, suggesting an increased dispersal capability in infected females. Conclusion  The spatial structure of infestation should be taken into account for the prioritization of vector control activities within villages, and spatially targeted interventions may be explored. A potential vector manipulation by T. cruzi, observed for the first time in triatomines, may favor parasite transmission to new hosts. Objectif:  la maladie de Chagas est une maladie parasitaire majeure a transmission vectorielle en Amerique latine, principalement transmise aux humains par les vecteurs triatomes. Les especes de triatomes non domicilies telles que Triatoma dimidiataa Mexico, dans la peninsule du Yucatan, peuvent transitoirement envahir les maisons et emerger en tant qu’un defi majeur pour la lutte contre la transmission de Trypanosoma cruzi aux humains. Nous avons analyse la propagation spatio-temporelle de l’infestation des maisons par T. dimidiata dans quatre villages. Methodes:  Les triatomes ont ete collectes dans quatre villages sur une periode de deux ans et les profils spatio-temporels des infestations ont ete analyses. Resultats:  Les triatomes etaient toujours plus abondants a la peripherie des villages que dans le centre, indiquant un risque beaucoup plus eleve de transmission de T. cruzia la peripherie. Les mâles de T. dimidiata ont ete plus retrouves vers le centre des villages, tandis que les femelles restaient plus pres de la peripherie, suggerant des differences de capacites de dispersion selon le sexe, meme si les moments de la dispersion semblaient identiques. De facon surprenante, les femelles infectees etaient systematiquement collectees dans des maisons situees beaucoup plus loin dans les buissons environnants que les femelles non infectees, alors que la repartition des mâles n’etait pas affectee par leur statut d’infection par T. cruzi, suggerant une capacite de dispersion plus elevee chez les femelles infectees. Conclusion:  La structure spatiale de l’infestation devrait etre prise en compte pour la hierarchisation des activites de lutte antivectorielle dans les villages et des interventions spatialement ciblees pourraient etre explorees. Une manipulation possible des vecteurs par T. cruzi, observee pour la premiere fois chez les triatomes, pourrait favoriser la transmission du parasite a de nouveaux hotes. Objetivo:  La enfermedad de Chagas es una enfermedad vectorial parasitaria importante en Latinoamerica, principalmente transmitida a los humanos por vectores triatominos. Las especies triatominas no domiciliadas, tales como Triatoma dimidiata en la Peninsula del Yucatan, Mejico, pueden invadir las casas transitoriamente y estan convirtiendose en un reto importante para el control de la transmision de Trypanosoma cruzi a humanos. Hemos analizado la dispersion espacio-temporal de la infestacion de hogares por T. dimidiata en cuatro poblados rurales. Metodos:  Se recolectaron triatominos en cuatro poblados rurales durante dos anos, y se analizaron los patrones espacio-temporales de infestacion. Resultados:  Los triatominos fueron consistentemente mas abundantes en la periferia de los poblados que en el centro de los mismos, indicando un mayor riesgo de transmision de T. cruzi en la periferia. Se hallaron machos de T. dimidiata mas cerca del centro del poblado, mientras que las hembras se mantenian en la periferia, sugiriendo una dispersion diferencial de capacidades entre sexos, aunque el tiempo de dispersion parecia ser identico. Sorprendentemente, las hembras infectadas fueron siempre recogidas dentro de casas mucho mas alejadas de los arbustos que las hembras no infectadas, mientras que la distribucion de los machos no se veia afectada por su estatus de infeccion con T. cruzi, sugiriendo una mayor capacidad de dispersion entre las hembras infectadas. Conclusion:  La estructura espacial de infestacion deberia tenerse en cuenta para la priorizacion de las actividades de control vectorial dentro de los poblados, y deberian explorarse las intervenciones con enfasis espacial. Una posible manipulacion vectorial de T. cruzi, observada por primera vez en triatominos, podria favorecer la transmision del parasito a nuevos hospederos.

Espinosa Silva, Yanis Ricardo - One of the best experts on this subject based on the ideXlab platform.

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    2020
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.Instituto de Física de Líquidos y Sistemas Biológico

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    'Corporacion Universitaria Autonoma del Cauca', 2018
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.Fil: Espinosa Silva, Yanis Ricardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Física de Líquidos y Sistemas Biológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Física de Líquidos y Sistemas Biológicos; ArgentinaFil: Galvis, Fredy. Universidade de Sao Paulo; BrasilFil: Maldonado Rozo, Adriana. Universidad Nacional de Colombia; Colombi

Galvis Fredy - One of the best experts on this subject based on the ideXlab platform.

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    2020
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.Instituto de Física de Líquidos y Sistemas Biológico

  • Purificación del antichagásico benznidazol a partir del preparado comercial Rochagan®: caracterización de los complejos de inclusión con β-ciclodextrina
    'Corporacion Universitaria Autonoma del Cauca', 2018
    Co-Authors: Espinosa Silva, Yanis Ricardo, Galvis Fredy, Maldonado Rozo Adriana
    Abstract:

    El Chagas es una enfermedad endémica del continente americano cuyo agente etiológico es el Trypanosoma cruzi. Actualmente, no hay una vacuna profiláctica para esta enfermedad o un tratamiento totalmente eficaz ´ para los casos crónicos. El Nifurtimox y el Benznidazol (BNZ) son complejos nitroheterocíclicos que se han utilizado desde finales de los anos 60 y principios de los a ˜ nos 70, principalmente para el tratamiento de infecciones congénitas y agudas. Sin embargo, estos medicamentos pueden causar una amplia variedad de efectos adversos. Especialmente, en el benznidazol es necesario desarrollar nuevas alternativas terapéuticas que mejoren su baja solubilidad en agua, la absorción gastrointestinal limitada, y su alta toxicidad.The Chagas is a endemic disease from the American continent whose etiological agent is the Trypanosoma cruzi. Currently, there is neither a prophylactic vaccine for this disease or a totally effective treatment for the chronic cases. The Nifurtimox and the benznidazole are nitroheterocyclic complexes that have been used since the end of the 60’s and the beginning of the 70’s, mainly for the treatment of congenital and acute infections. However, these medications can cause a wide variety of adverse effects. Especially, in the benznidazole is necessary to develop new therapeutic alternatives which improve its low solubility in water, the limited gastrointestinal absorption, and the high toxicity. Because of the difficulties that often occur in the achievement of pre-synthesis Benznidazole, high costs in the synthesis process and buy the active compound in countries with limited research economics commodities. We have proposed a method of purification in order to facilitate the experimental procedures from the commercial preparation Rochegan®, obtaining BNZ viable for the formation of the controlled release complex with β-cyclodextrin (βCD) and the characterization of the BNZ-βCD inclusion complex.Fil: Espinosa Silva, Yanis Ricardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Física de Líquidos y Sistemas Biológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Física de Líquidos y Sistemas Biológicos; ArgentinaFil: Galvis, Fredy. Universidade de Sao Paulo; BrasilFil: Maldonado Rozo, Adriana. Universidad Nacional de Colombia; Colombi

Maria Inês De Paula Leão - One of the best experts on this subject based on the ideXlab platform.

  • Estudo clínico e epidemiológico de pacientes submetidos a implante de marcapasso cardíaco artificial permanente: comparação dos portadores da doença de Chagas com os de doenças degenerativas do sistema de condução Clinical and epidemiological characteristics of patients with Chagas' disease submitted to permanent cardiac pacemaker implantation
    Sociedade Brasileira de Cirurgia Cardiovascular, 2004
    Co-Authors: Roberto Costa, Anis Rassi, Maria Inês De Paula Leão
    Abstract:

    OBJETIVO: Estudar os pacientes portadores de marcapasso cardíaco artificial permanente, comparando as características clínicas e epidemiológicas dos portadores da doença de Chagas com a dos portadores de doenças degenerativas do sistema de condução. MÉTODO: Foram analisados 57.632 procedimentos cadastrados no Registro Brasileiro de Marcapassos, realizados no período de 1995 a 2003, sendo: 25.648 pacientes portadores da doença de Chagas e 31.984, de doenças degenerativas. A comparação das características dessas populações foi feita pelos testes do Qui-quadrado e t-Student com nível de significância de 5%. RESULTADOS: Houve predomínio da doença de Chagas na região Centro-Oeste, nos implantes iniciais. Nas reoperações, a população chagásica representou maioria também no Sudeste. A idade dos pacientes chagásicos foi 58,6 ± 15,3 e 59,3 ± 14,8 anos, respectivamente para implantes iniciais e reoperações, e, nos não chagásicos, 73,5 ± 12,6 e 73,7 ± 13,5. Não foi notada diferença na distribuição entre os dois sexos. Houve maior ocorrência de síncopes, pré-síncopes e bloqueio atrioventricular com QRS largo nos pacientes chagásicos e de tonturas, insuficiência cardíaca e QRS estreito nos não chagásicos. O modo de estimulação ventricular foi utilizado em 60% e 63% nos implantes iniciais e em 77% e 76% das reoperações, respectivamente para os pacientes chagásicos e não chagásicos. A depleção da bateria por desgaste normal foi o principal motivo para reoperação dos pacientes, tendo ocorrido em 76,1% e 79,6% das reoperações, respectivamente para chagásicos e não chagásicos. CONCLUSÕES: Os dados analisados demonstraram diferenças significativas nas características clínicas e demográficas das populações estudadas.OBJECTIVE: To study patients with permanent cardiac pacemakers, comparing the clinical and epidemiological characteristics of patients with Chagas' disease versus the ones with degenerative or ischemic diseases. METHOD: 57,632 procedures performed from 1995 to 2003, registered in the Brazilian Pacemaker Register were analyzed: 25,648 patients with Chagas' disease and 31,984 with degenerative or ischemic bradiarrythmias. The comparison of the characteristics of these two populations included Chi-square and t-Student tests, with a 5% level of significance. RESULTS: There was a predominance of the Chagas' disease in the Centar-west region, in the initial implantations. In re-operations, the population with Chagas' disease represented majority in the Southeast, too. Mean age was 59.3 ± 15.3 and 58.6 ± 14.8, respectively for initial implantations and re-operations in Chagas' disease patients and 73.5 ± 12.6 and 73.7 ± 13.5, in non Chagas'disease patients. There was no difference in respect to both genders and etiology. Syncope episodes and 3rd degree AV block with wide QRS were more frequent in patients with Chagas' disease, and dizziness, heart failure and 3rd degree AV block with in the other patients. Ventricular pacing systems were used in 60% and 63% in the initial implants and 77% and 76% of the reoperations, respectively for Chagas' and non-Chagas' disease patients. The need to change the batteries was the main reason for reoperations in 76.1% and 79.6% of these procedures, respectively for patients with Chagas' disease and the other causes of bradicardia. CONCLUSIONS: The analysis of data of these two populations demonstrated significant differences in the clinical and demographic characteristics

  • Experiência brasileira com uso de marcapasso cardíaco artificial: resultados atuais obtidos pelo Registro Brasileiro de Marcapassos - RBM Brazilian permanent cardiac pacemaker implantation experience: results obtained from the Brazilian Pacemaker Register's data
    Sociedade Brasileira de Cirurgia Cardiovascular, 1995
    Co-Authors: Roberto Costa, Maria Inês De Paula Leão
    Abstract:

    FUNDAMENTOS: Registro Brasileiro de Marcapassos (RBM) é uma base nacional de dados que tem por finalidade coletar e divulgar informações concernentes aos procedimentos cirúrgicos realizados em pacientes com estimulação cardíaca artificial permanente em todo o Brasil. OBJETIVO: Apresentar os resultados obtidos no período de junho a dezembro de 1994. CASUÍSTICA: No período de 1/6/94 a 31/12/94 foram recebidos 4696 formulários enviados por 130 hospitais e 287 médicos. Os procedimentos referiam-se a 3403 (72,5%) implantes iniciais a 1053 (22,4%) reoperações e 240 (5,1%) formulários exibiam este campo de cadastramento como dado não disponível. RESULTADOS: Dos 3403 pacientes submetidos a implante inicial, 52,8% eram do sexo masculino e 73,7% eram da raça branca. Sintomas de hipofluxo cerebral justificaram o implante em 76,4% dos pacientes e a insuficiência cardíaca congestiva esteve presente em 85,0% dos casos, sendo que em 266 (7,9%) pacientes foi a causa principal para a operação. Os achados eletrocardiográficos predominantes foram: bloqueio atrioventricular total (57,7%); disfunção do nó sinusal (13,9%), bloqueio AV do 2º grau (13,8%); e flütter ou fibrilação atrial com baixa resposta ventricular (6,6%). A doença de Chagas foi a etiologia predominante (30,4%). Implante de marcapasso ventricular foi realizado em 83,6% dos pacientes e atrioventricular em 16,1%. Dos 1053 casos de reoperações informados, 50,4% ocorreram por problemas no gerador de pulsos. O tempo transcorrido entre o implante inicial e a cirurgia atual variou de 1 mês a 24 anos, com média de 7,1 anos. A susbstituição do gerador de pulsos foi informada em 917 pacientes (87,0% dos casos de reoperação); sendo a principal causa de troca o esgotamento por fim de vida em 65,7%. A substituição de eletrodo atrial foi relatada em 21 pacientes e de eletrodo ventricular em 203 pacientes. CONCLUSÕES: A participação ativa de todos os membros do Departamento de Estimulação Cardíaca Artificial (DECA), com o apoio das empresas fornecedoras de marcapasso, e o respaldo do Ministério da Saúde permitiram que a implantação do RBM ocorresse da forma mais tranqüila possível. Hoje se dispõe de uma estatística nacional, volumosa e confiável, sobre a cirurgia de marcapasso no Brasil. As dificuldades enfrentadas estão relacionadas, principalmente, à estrutura individual de coleta de dados e a graus variados de familiaridade com o formulário, dificuldades estas que, com o tempo, tenderão a desaparecer.BACKGROUND: Brazilian Pacemaker Registry (RBM) is a nationwide database to collect informations about all permanent pacemaker procedures performed in Brazil. It is a task force composed by Medical Society, Health Ministeryand Pacemaker Companies. OBJECTIVE: To report the data obtained from June to December, 1994. METHODS: From June 1 st to December 31,1994,4696 surgical procedures for permanent cardiac pacing were informed. These procedures were 3403 (72,5%) initial implantations, 1053 (22.4%) re-operations and in 240 cases this information was non-available. RESULTS: From 3403 initial implantations informed, 52.8% were males and 73.7% Caucasians. Preoperative dizziness or syncopes were refered in 76.4% and congestive heart failure in 85.0% of the patients. EKG evaluation showed 3rd degree atrioventricular (AV) block in 57.7%, sick sinus syndrome in 13.9%, 2nd degree AV block in 13.8%, and high degree AV block and flutter or atrial fibrillation in 6.6% of patients. Chaga's disease was the prédominât ethiology (30.4%). Ventricular pacemakers were implanted in 83.6% of cases, atrioventricular in 16.1 % and atrial pacing in 0.3%. In the 1053 cases of re-operation, the interval between the initial implantation and the present procedure ranged from 1 month to 24 years (M=7.1 years). Pulse generator replacements were refered in 917 patients (87.0% of re-operation procedures), 65.7% of them at the end of life. Atrial lead replacement were performed in 21, and ventricular lead replacement in 203 patients